Abstract
Pediatric surgical trials are rare and the impact of such trials on the institutions in which they are conducted is unknown. The purpose of this study was to analyze the clinical and financial impact of The Re-MATCH trial, a Phase I clinical trial requiring the biopsy or resection of recurrent medulloblastoma or PNET for enrollment. Inpatient financial and clinical volume information was collected during the 3 years of trial enrollment and the years preceding and following it. The primary endpoints were the difference in direct contribution margin (DCM), or net gain, of study and non-study patients and the difference in surgical volume during the study and non-study periods. The trial enrolled 18 patients; 15 had surgery at the sponsor institution and three had surgery at their home institution, then transferred tumor material to the sponsor institution. There were no differences between the two groups for potentially confounding variables such as neurosurgical procedure work relative value units (P = 0.13) or insurance provider (P = 0.26). There was no difference between the inpatient DCM per case for the institution for non-study patients (mean ± SD, $9039 ± $28,549) and study patients ($14,332 ± $20,231) (P = 0.4819). During the non-study period, there were a mean of 2.78 ± 1.65 pediatric brain tumor resections per month compared to 3.34 ± 1.66 cases per month during the study period, a 17% increase. When the 15 study patients were excluded, there were 2.97 ± 1.64 cases per month, a 7% increase. However, this increase in total case volume including study and non-study patients was not significant (P = 0.121). Phase I investigator-initiated surgically-based clinical trials may increase institutional surgical volume without imposing a financial burden. Finances are unlikely to be a barrier for researchers negotiating for resources to conduct such trials.
Similar content being viewed by others
References
Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG, Siddiqui U, Mahmoud N, Parkin PC (2010) Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985–2005. Arch Pediatr Adolesc Med 164(3):283–288. doi:10.1001/archpediatrics.2009.291
Caldwell PH, Murphy SB, Butow PN, Craig JC (2004) Clinical trials in children. Lancet 364(9436):803–811. doi:10.1016/S0140-6736(04)16942-0
Institue NC (20016) SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML). National Institute of Health. http://seer.cancer.gov/statfacts/html/amyl.html
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R (2015) Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children’s Oncology Group. Pediatr Blood Cancer 62 (10):1775–1781. doi:10.1002/pbc.25569
Burwell SM (2014) The Department of Health and Human Services 2014 Annual Report on the Quality of Care for Children in Medicaid and CHIP
American Hospital Assocition (2006–2016) Financial Fact Sheets. http://www.aha.org/research/policy/finfactsheets.shtml
Pizer B, Donachie PH, Robinson K, Taylor RE, Michalski A, Punt J, Ellison DW, Picton S (2011) Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children’s Cancer and Leukaemia Group study. Eur J Cancer 47(9):1389–1397. doi:10.1016/j.ejca.2011.03.004
Messali A, Hay JW, Villacorta R (2013) The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro-oncology 15(11):1532–1542. doi:10.1093/neuonc/not096
Russell HV, Panchal J, Vonville H, Franzini L, Swint JM (2013) Economic evaluation of pediatric cancer treatment: a systematic literature review. Pediatrics 131(1):e273–e287. doi:10.1542/peds.2012-0912
Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD (2012) Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 130(2):285–292. doi:10.1542/peds.2012-0139
Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK Jr (2007) Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297(5):480–488. doi:10.1001/jama.297.5.480
Acknowledgements
The authors thank Ryan Stephenson, Josh MacIver, and Susan Pickard for their assistance in obtaining financial data. The project was funded by the Pediatric Brain Tumor Foundation of the United States (DAM, JHS) and the Department of Defense Clinical Trial Award #W81XWH-10-1-0089 (DAM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have disclosures or conflicts of interest.
Rights and permissions
About this article
Cite this article
Thompson, E.M., Gururangan, S., Grant, G. et al. The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. J Neurooncol 132, 83–87 (2017). https://doi.org/10.1007/s11060-016-2338-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-016-2338-z